Navigation Links
Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Date:11/11/2009

icularly those anticipating future clinical and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website and in the American Society of Hematology's website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
        Lauren Fischer
        Director - Investor Relations
        Keryx Biopharmaceuticals, Inc.
        Tel: 212.531.5965
        E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
4. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
5. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
6. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015  Physicians and payers alone do not ... Patients are better informed and getting increasingly involved ... This shift in power is reshaping the healthcare ... marketing. As part of this evolving ... important to educate, communicate and engage patients throughout ...
(Date:7/31/2015)... , July 31, 2015  In today,s ever-changing marketplace, ... are increasingly mobile, increasingly connected, and increasingly impatient with ... of customer interaction channels and tools is driving call ... media. According to research by benchmarking ... counter (OTC) segment in a call center study realize ...
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is reporting ... issued a warning letter to C.R. Bard, the manufacturer of ... adequate strides to correct violations the agency found at two ... violations after the FDA cited them during Inspectional Observations that ... Bard,s Tempe, AZ , location and on ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... presented at the 10th International Kidney Cancer Symposium ... pretreatment blood-based test, VeriStrat, was able to stratify ... combination of two targeted therapies, sunitinib (Sutent®) and ... tested VeriStrat Good had significantly longer progression free ...
... 14, 2011 Reata Pharmaceuticals, Inc. announced Friday a ... company,s lead program, bardoxolone methyl, and to continue advancing ... the following executives: Paul Audhya, MD, ... Hilary Malone, Ph.D., as Vice President and ...
Cached Medicine Technology:VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 2VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 3Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 2Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 3
(Date:7/31/2015)... ... ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and black diamond award ... fat reduction in New York. Due to its unparalleled level of experience for ... patients travel to New York to get their non-surgical skin tightening and body shaping ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 ... ... the five new industry players to know in predictive health analytics , ... machine learning technologies. The firm creates predictive software that targets patient and population ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, the Mesothelioma ... store can be accessed by visiting http://www.curemeso.org/store . , “Our new store ... best part: whenever a product is purchased, the Meso Foundation receives a $5.00 ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight ... Memphis on October 3, 2015. The Ride to Fight On is a cycling fundraiser ... Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. A ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical ... PRO this week. Zeltiq Aesthetics released this new applicator in the United States ... for treating the outer thighs. The original applicator required a 2 hour treatment ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Inc. ("Astellas") recently hired Walt Johnston as vice president ... president of marketing & sales, Johnston will be responsible ... and development products for the United States business."Walt is ... values. We are excited to add him to our ...
... division of Elsevier, would like to announce the ... Evidence-Based Addiction Treatment by Peter Miller, PhD. ... effectiveness in the field of addictions treatment is ... Inconsistent practices based solely on clinical intuition rather ...
... An experimental drug derived from cottonseed shows promise ... the most lethal brain cancer, said researchers at the ... results are from a Phase II clinical trial of ... cottonseed that overcomes the abnormal growth patterns of tumor ...
... The Initial Rush is On, So Consumers Should Get This Deliciously ... One of the most widely anticipated product launches of the season ... such as phones and video games, but consumers can,t wait to ... (R) Special K ...
... (NYSE Amex: CXM ) and its subsidiary ... "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment ... Trials Symposium at the American Society of Gene Therapy ... 27, 2009. Dr. Barbara K. Sosnowski, Cardium,s Vice ...
... Mass., May 28 Echo Therapeutics, Inc. (OTC ... signed a license agreement with Ferndale Pharma Group ... to develop, market, sell and distribute Echo,s Prelude(TM) ... preparation prior to the application of topical 4% ...
Cached Medicine News:Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 2Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 3Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 4Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 2Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 3Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 4Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 5Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 6Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 7Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 8Health News:Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine 2Health News:Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine 3Health News:Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine 4
... Tri-Active is the result of ... the combination of three different methods ... to your skin. This treatment is ... of cellulite through the combined action ...
... is a CO2 laser system with CW ... for dealing with all therapeutic application in ... supplies medium-to-high intensities in super-pulsed mode, designed ... surgery. It is also capable of supplying ...
... the latest evolution of Smartepil family by ... system for epilation and transdermic vascular treatments. ... modern software, Smartepil II Plus allows for ... respect of the patients social life. The ...
... offers a new and efficient method applied ... Springing from ongoing research and development with ... just a light source, but rather a ... represents new horizons in pulsed-light-based technology, the ...
Medicine Products: